The Role of Aurora-A in Human Cancers and Future Therapeutics

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2020 Oct 12

PMID 33042612

Citations 23

Authors

Xinrong Lin

Xiaosong Xiang

Liping Hao

Ting Wang

Yongting Lai

Mubalake Abudoureyimu

Hao Zhou

Bing Feng

Xiaoyuan Chu

Rui Wang

Affiliations

Soon will be listed here.

Abstract

Aurora-A is a mitotic serine/threonine-protein kinase and an oncogene. In normal cells, Aurora-A appears from G2 phase and localizes at the centrosome, where it participates in centrosome replication, isolation and maturation. Aurora-A also maintains Golgi apparatus structure and spindle assembly. Aurora-A undergoes ubiquitination-mediated degradation after the cell division phase. Aurora-A is abnormally expressed in tumor cells and promotes cell proliferation by regulating mitotic substrates, such as PP1, PLK1, TPX2, and LAST2, and affects other molecules through a non-mitotic pathway to promote cell invasion and metastasis. Some molecules in tumor cells also indirectly act on Aurora-A to regulate tumor cells. Aurora-A also mediates resistance to chemotherapy and radiotherapy and is involved in tumor immunotherapy. Clinical trials of Aurora-A molecular inhibitors are currently underway, and clinical transformation is just around the corner.

Citing Articles

Ligand-centred phenotype-driven development of potent kinase inhibitors against oesophageal cancer.

Ayala-Aguilera C, Ge Y, Lorente-Macias A, Jones B, Adam C, Carragher N RSC Med Chem. 2024; .

PMID: 39493221 PMC: 11528321. DOI: 10.1039/d4md00579a.

Mitotic kinases are emerging therapeutic targets against metastatic breast cancer.

Aquino-Acevedo A, Orengo-Orengo J, Cruz-Robles M, Saavedra H Cell Div. 2024; 19(1):21.

PMID: 38886738 PMC: 11184769. DOI: 10.1186/s13008-024-00125-x.

Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study.

Winter P, Fuksiewicz M, Jagiello-Gruszfeld A, Nowecki Z, Kotowicz B Cancers (Basel). 2023; 15(22).

PMID: 38001709 PMC: 10670120. DOI: 10.3390/cancers15225446.

Emerging roles of Aurora-A kinase in cancer therapy resistance.

Zheng D, Li J, Yan H, Zhang G, Li W, Chu E Acta Pharm Sin B. 2023; 13(7):2826-2843.

PMID: 37521867 PMC: 10372834. DOI: 10.1016/j.apsb.2023.03.013.

Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis.

Jingtai Z, Linfei H, Yuyang Q, Ning K, Xinwei Y, Xin W Cell Death Dis. 2023; 14(3):224.

PMID: 36990998 PMC: 10060208. DOI: 10.1038/s41419-023-05709-z.

References

Kastankova I, Polakova I, Duskova M, Smahel M . Combined Cancer Immunotherapy Against Aurora Kinase A. J Immunother. 2016; 39(4):160-70. DOI: 10.1097/CJI.0000000000000120. View

Heo S, Noh E, Jeong Y, Ju L, Sung J, Yu H . Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression. Tumour Biol. 2019; 41(5):1010428319848612. DOI: 10.1177/1010428319848612. View

Weinlich R, Oberst A, Beere H, Green D . Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol. 2016; 18(2):127-136. DOI: 10.1038/nrm.2016.149. View

Shen Z, Chen Y, Huang G, Zhu X, Wang R, Chen L . Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-κB signaling pathway. BMC Cancer. 2019; 19(1):1075. PMC: 6842208. DOI: 10.1186/s12885-019-6312-y. View

Kesisova I, Nakos K, Tsolou A, Angelis D, Lewis J, Chatzaki A . Tripolin A, a novel small-molecule inhibitor of aurora A kinase, reveals new regulation of HURP's distribution on microtubules. PLoS One. 2013; 8(3):e58485. PMC: 3596387. DOI: 10.1371/journal.pone.0058485. View

Chan C, Botstein D . Isolation and characterization of chromosome-gain and increase-in-ploidy mutants in yeast. Genetics. 1993; 135(3):677-91. PMC: 1205712. DOI: 10.1093/genetics/135.3.677. View

Kuang P, Chen Z, Wang J, Liu Z, Wang J, Gao J . Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer. Transl Oncol. 2017; 10(3):367-377. PMC: 5397579. DOI: 10.1016/j.tranon.2017.02.010. View

Umstead M, Xiong J, Qi Q, Du Y, Fu H . Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling. Oncotarget. 2017; 8(17):28359-28372. PMC: 5438655. DOI: 10.18632/oncotarget.15049. View

Berdnik D, Knoblich J . Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. Curr Biol. 2002; 12(8):640-7. DOI: 10.1016/s0960-9822(02)00766-2. View

10.

Min Y, Kim W, Kim J . The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation. Oncotarget. 2016; 7(51):84718-84735. PMC: 5356694. DOI: 10.18632/oncotarget.12448. View

11.

Traynor A, Hewitt M, Liu G, Flaherty K, Clark J, Freedman S . Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010; 67(2):305-14. PMC: 3050703. DOI: 10.1007/s00280-010-1318-9. View

12.

Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway N . Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep. 2017; 7:40714. PMC: 5244380. DOI: 10.1038/srep40714. View

13.

Boss D, Witteveen P, van der Sar J, Lolkema M, Voest E, Stockman P . Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2010; 22(2):431-7. DOI: 10.1093/annonc/mdq344. View

14.

Hay A, Murugesan A, DiPasquale A, Kouroukis T, Sandhu I, Kukreti V . A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leuk Lymphoma. 2015; 57(6):1463-6. DOI: 10.3109/10428194.2015.1091927. View

15.

Chen C, Song G, Xiang J, Zhang H, Zhao S, Zhan Y . AURKA promotes cancer metastasis by regulating epithelial-mesenchymal transition and cancer stem cell properties in hepatocellular carcinoma. Biochem Biophys Res Commun. 2017; 486(2):514-520. DOI: 10.1016/j.bbrc.2017.03.075. View

16.

Jacobsen A, Bosch L, Martens-de Kemp S, Carvalho B, Sillars-Hardebol A, Dobson R . Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer. Sci Rep. 2018; 8(1):7522. PMC: 5951826. DOI: 10.1038/s41598-018-24982-z. View

17.

Willems E, Dedobbeleer M, Digregorio M, Lombard A, Goffart N, Lumapat P . Aurora A plays a dual role in migration and survival of human glioblastoma cells according to the CXCL12 concentration. Oncogene. 2018; 38(1):73-87. PMC: 6755987. DOI: 10.1038/s41388-018-0437-3. View

18.

Sankaran S, Crone D, Palazzo R, Parvin J . Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation. Cancer Res. 2007; 67(23):11186-94. DOI: 10.1158/0008-5472.CAN-07-2578. View

19.

Zhou X, Pant S, Nemunaitis J, Lockhart A, Falchook G, Bauer T . Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies. Invest New Drugs. 2017; 36(2):248-258. PMC: 5869871. DOI: 10.1007/s10637-017-0499-z. View

20.

Park S, Lin C, Ren N, Angus S, Dittmer D, Foote M . Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. Target Oncol. 2019; 14(5):563-575. PMC: 6893856. DOI: 10.1007/s11523-019-00662-4. View